New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
12:25 EDTCYBXCyberonics says short-seller report not accurate view of therapy biz, DJ reports
News For CYBX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 8, 2014
11:51 EDTCYBXCyberonics reports new results from E-36, E-37 studies
Cyberonics announced new results from two multi-site clinical studies of the AspireSR generator, E-36 and E-37, at the AES Annual Meeting in Seattle, Washington. Investigators presented results from the European E-36 study and the U.S. E-37 study, which assessed the acute impact of the AspireSR generator on seizure duration and termination, as well as the long-term evaluation of safety, clinical benefit of the automatic stimulation feature, and quality of life. Assessments of seizure severity and quality of life were made using validated scales scored by patients and physicians. The acute impact of the AspireSR generator on seizure duration and termination was evaluated during the Epilepsy Monitoring Unit stay period experienced by all patients in both studies. Seizure activity was recorded using concurrent video-EEG and ECG monitoring. Patients in both studies experienced termination of seizures as well as reduced seizure duration during automatic stimulation compared to historical controls. The AspireSR generator is currently investigational in the U.S. and not approved for commercial use. The AspireSR generator attained the CE Mark and is now available in an increasing number of European countries.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use